Opioid Withdrawal
1
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
US WorldMedsKY - Louisville
2 programsLofexidinePHASE_31 trial
Lofexidine Oral TabletPHASE_41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
US WorldMedsLofexidine Oral Tablet
US WorldMedsLofexidine
BioXcel TherapeuticsDexmedetomidine
SPARK BiopharmaEmbracePlus Smartwatch
Clinical Trials (4)
Total enrollment: 537 patients across 4 trials
Lofexidine for Adults Undergoing Lumbar Spine Surgery
Start: Sep 2019Est. completion: Apr 20216 patients
Phase 4Completed
Open-Label, Safety Study of Lofexidine
Start: Feb 2015Est. completion: Oct 2015286 patients
Phase 3Completed
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
Start: Jun 2020Est. completion: Feb 2021225 patients
Phase 1/2Completed
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
Start: Feb 2025Est. completion: May 202720 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 537 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.